Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin
A propensity score matched analysis
Gregory Y. H. Lip
1
University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK
2
Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
,
Allison Keshishian
3
STATinMED Research, Ann Arbor, Michigan, USA
,
Shital Kamble
4
Bristol-Myers Squibb Company, Princeton, New Jersey, USA
,
Xianying Pan
4
Bristol-Myers Squibb Company, Princeton, New Jersey, USA
,
Jack Mardekian
5
Pfizer, Inc., New York, New York, USA
,
Ruslan Horblyuk
5
Pfizer, Inc., New York, New York, USA
,
Melissa Hamilton
4
Bristol-Myers Squibb Company, Princeton, New Jersey, USA